AI Tool Detects Parkinson’s Up To 15 Years Early With 96% Accuracy

Health & Lifestyle
444

Listen to article (english)

Translate to Spanish or other 102 languages!

Researchers developed an AI tool to predict Parkinson’s disease from blood samples. Image for illustration purposes
Researchers developed an AI tool to predict Parkinson’s disease from blood samples. Image for illustration purposes

Medical News Today

- Advertisement -
  • Researchers developed an AI tool to predict Parkinson’s disease from blood samples. 
  • The tool can predict Parkinson’s 15 years before symptom onset with 96% accuracy. 
  • The underlying technology could possibly be adapted for diagnosing other conditions. 

Parkinson’s disease is a neurodegenerative condition characterizedTrusted Source by unintended movements such as shaking, stiffness, and difficulty balancing. It is caused by the loss of nerve cells in the brain, leading to reduced levels of dopamine, which plays a key role in movement.

To read the full story on Medical News Today Follow the link below: 

https://www.medicalnewstoday.com/articles/ai-tool-detects-parkinsons-up-to-15-years-early-with-96-accuracy?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2023-05-18&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
STC & Texas A&M Unite to Meet Health Care Needs
Next article
Importance of Routine Checkups for Women

More Articles

Texas Adds New Condition to Mandatory Newborn Screening Tests

The Texas Department of State Health Services added a new enzyme deficiency test on June 1, 2026, to its newborn screening panel, meaning that all Texas newborns are now tested for 60 rare, genetic conditions. Tests for hearing loss and critical congenital heart disease are additional point-of-service tests typically conducted by the birthing center. 

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

STHS GME Consortium Encourages Community to “Walk with a Doc”, June 6th

Mega Doctor News In an era defined by high-intensity workouts, wearable fitness trackers and advanced training techniques, one of simplest...

Study: Menopause Hormone Therapy Declines Nationwide Despite Proven Benefits

Hormone therapy use among women in the U.S. remains low, even though it's an effective treatment for many menopause symptoms, according to a new Mayo Clinic study published in Mayo Clinic Proceedings.
- Advertisement -